This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Erectile dysfunction, exclusion
ERECTILE_EXCLUSION
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleonly males |
244368 |
2. Check conditionsNone |
244368 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
152 |
4. Check minimum number of eventsNone |
152 |
5. Include endpointsNone |
152 |
6. Filter based on genotype QC (FinnGen only) |
134 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- I27
- Name in latin
- Hypertensio pulmonalis primaria
Similar endpoints
↥List of similar endpoints to
Erectile dysfunction, exclusion
based on the number of shared cases.
Similar with more cases:
- Secondary right heart disease
- Other pulmonary heart/vessel disease
- Pulmonary heart disease, diseases of pulmonary circulation
- Cardiovascular diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 134 | - | 134 |
| Unadjusted period prevalence (%) | 0.06 | - | 0.06 |
| Median age at first event (years) | 66.53 | - | 66.53 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 139
- Matched controls
- 1390
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I27.0
ICD-10 Finland
Primary pulmonary hypertension
+∞
130.7
104
*
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
110.0
47.9
50
7
I27.9
ICD-10 Finland
Pulmonary heart disease, unspecified
191.8
41.3
41
*
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
185.3
40.1
40
*
G04BE03
ATC
sildenafil; oral
87.8
39.9
43
7
C03DA01
ATC
spironolactone; oral
9.2
36.5
61
109
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
11.0
34.5
44
56
4168X
ICD-9 Finland
Chronic pulmonary heart disease, Other chronic pulmonary heart diseases
+∞
33.7
31
*
I27.8
ICD-10 Finland
Other specified pulmonary heart diseases
347.5
28.9
28
*
C03CA01
ATC
furosemide; systemic
7.7
28.5
104
387
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
6.1
25.3
69
193
C02KX04
ATC
macitentan; oral
+∞
19.2
18
*
B01AA03
ATC
warfarin; systemic
4.8
18.8
68
231
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
7.1
18.6
32
56
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
4.5
17.5
69
248
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.7
17.1
55
169
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
6.8
16.3
29
52
C01AA05
ATC
digoxin; systemic
5.1
15.9
42
109
R06.0
ICD-10 Finland
Dyspnoea
4.0
14.8
66
254
4912B
ICD-9 Finland
Chronic bronchitis, Obstructive chronic bronchitis[BRONCHITIS OBSTRUCTIVA CUM EMPHYSEMATE]
15.9
14.3
23
17
J96.1
ICD-10 Finland
Chronic respiratory failure
15.0
14.0
23
18
C02KX01
ATC
bosentan; oral
+∞
13.8
13
*
AP2
HP
Catheterization of the right side of the heart
154.5
13.7
14
*
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
12.4
13.4
24
23
G04BE08
ATC
tadalafil; oral
77.1
12.8
14
*
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
23.9
12.3
17
8
I50.9
ICD-10 Finland
Heart failure, unspecified
3.8
12.3
53
195
I26.0
ICD-10 Finland
Pulmonary embolism with mention of acute cor pulmonale
14.4
12.1
20
16
H02AB06
ATC
prednisolone; systemic
3.4
11.5
86
445
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
5.7
11.2
23
47
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.4
11.0
57
234
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
12.7
10.9
19
17
201
Kela drug reimbursment
Chronic cardiac insufficiency
4.4
10.7
31
85
TPH04
NOMESCO Finland
Cathetrisation of vein
3.5
10.7
50
192
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
10.4
86
463
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
9.0
10.1
21
27
ZXE30
NOMESCO Finland
More than five and less than seven hours
6.0
9.9
19
36
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
5.3
9.7
21
45
WX740
NOMESCO Finland
Nitrogen oxide therapy
107.0
9.5
10
*
XF620
NOMESCO Finland
Examination of circulation with color method
107.0
9.5
10
*
205
Kela drug reimbursment
Chronic hypertension
3.0
9.2
60
278
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
4.3
8.8
25
67
4289X
ICD-9 Finland
Heart failure, unspecified
17.7
8.7
13
8
R28
ICPC
Limited function/disability (R)
29.6
8.6
11
*
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
10.5
8.5
16
17
GD2SN
NOMESCO Finland
Lung ventilation SPECT
95.6
8.5
9
*
B01AC27
ATC
selexipag; oral
+∞
8.4
8
*
383
Kela drug reimbursment
Selexipag
+∞
8.4
8
*
C02KX05
ATC
riociguat; oral
+∞
8.4
8
*
XF622
NOMESCO Finland
Measurement of minute volume of heart
35.6
8.2
10
*
I50.0
ICD-10 Finland
Congestive heart failure
3.6
7.7
29
95
GD1UN
NOMESCO Finland
Lung circulation SPECT
84.4
7.5
8
*
XF614
NOMESCO Finland
Measurement of pulmonary artery pressure
84.4
7.5
8
*
FB1BC
NOMESCO Finland
Extensive angiography of arteria pulmonalis
+∞
7.4
7
*
C02KX02
ATC
ambrisentan; oral
+∞
7.4
7
*
R4110
NOMESCO Finland
Physiotherapy
2.8
7.3
49
226
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.3
7.3
20
52
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.8
7.2
24
72
M04AA01
ATC
allopurinol; systemic
3.0
7.2
39
160
Z2221
NOMESCO Finland
Medical doctor
2.8
6.7
44
199
R03AC02
ATC
salbutamol; inhalant
2.5
6.7
80
484
Z3226
NOMESCO Finland
Physiotherapist
3.0
6.7
35
140
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
15.3
6.5
10
7
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
8.8
6.5
13
16
WX872
NOMESCO Finland
Intensive care
5.6
6.5
18
36
R03BB01
ATC
ipratropium bromide; inhalant
3.9
6.4
20
57
A12BA01
ATC
potassium chloride; oral
4.4
6.4
17
43
B01AB05
ATC
enoxaparin; parenteral
2.6
6.4
49
240
L04AA06
ATC
mycophenolic acid; systemic
19.1
6.3
9
5
K93
ICPC
Pulmonary embolism
28.1
6.3
8
*
A46
ICD-10 Finland
Erysipelas
2.9
6.3
35
145
XF400
NOMESCO Finland
ECG with 12 standard connections
2.7
6.2
40
179
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.9
6.1
32
128
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
25
35
8.49
17.58
9.1
2.5
0.31
0.30
iu/ml
0.08
19
19
20
10
23.07
14.26
1.4
1.4
—
—
—
0
0
45
148
4.02
12.28
19.8
13.6
1.00
0.47
mmol/l
0.25
33
126
32
107
3.59
8.28
2.8
2.7
0.19
0.22
g/l
1.05
32
96
11
5
23.69
8.15
1.2
1.6
—
—
—
0
0
46
207
2.83
7.14
16.8
1.6
1.75
2.17
mg/l
0.32
37
170
11
8
14.79
7.02
1.2
1.4
—
—
—
0
0
34
131
3.11
6.95
8.7
5.3
2.03
1.02
mmol/l
0.63
29
99
28
97
3.36
6.79
30.4
12.1
25.00
24.42
mmol/l
0.25
28
97
76
455
2.48
6.44
11.5
5.7
34.70
35.16
g/l
0.28
71
432
37
156
2.87
6.42
3.1
1.9
—
—
—
0
0
36
150
2.89
6.38
3.2
2.0
—
—
—
0
0
9
5
19.08
6.35
1.1
1.2
—
—
—
0
0
34
138
2.94
6.31
8.9
5.3
5.95
5.66
kpa
0.75
34
130
82
538
2.28
5.28
23.0
7.2
15.37
13.55
umol/l
0.67
82
523
15
40
4.08
5.25
2.8
2.9
—
—
—
0
0
12
20
6.46
5.04
10.3
8.4
10.81
9.82
mg/l
0.28
12
20
29
126
2.64
4.66
1.3
1.3
39.14
30.46
iu/ml
—
7
35
13
27
5.20
4.63
2.8
1.3
—
—
—
0
0
39
199
2.33
4.46
3.2
2.1
—
—
—
0
0
17
58
3.20
4.18
6.5
4.4
24.18
24.13
mmol/l
0.02
17
53
8
10
8.40
4.12
1.0
1.0
—
—
—
0
0
66
434
1.99
3.84
7.2
4.5
310.75
48.73
ng/l
0.44
57
335
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
6
5
12.45
3.80
2.5
1.0
217.33
112.80
%
—
6
5
20
80
2.75
3.74
9.2
5.7
25.00
23.36
mmol/l
1.24
20
80
16
60
2.88
3.36
2.6
1.5
—
—
—
0
0
25
122
2.28
3.11
7.4
4.2
4.97
4.56
kpa
0.52
25
113
9
21
4.51
3.05
1.2
1.4
—
—
—
0
0
5
5
10.30
3.00
1.4
1.4
—
—
—
0
0
80
593
1.82
2.99
15.1
10.9
4.79
4.33
e9/l
0.74
71
515
6
184
0.30
2.96
2.5
2.3
9.44
14.21
nmol/l
—
6
174
20
92
2.37
2.83
2.4
1.5
—
—
—
0
0
11
34
3.42
2.80
2.2
1.3
—
—
—
0
0
5
6
8.58
2.77
1.4
1.3
96.60
79.67
%
—
5
6
7
14
5.20
2.76
3.0
1.4
—
—
—
0
0
6
10
6.21
2.72
2.0
1.4
187.33
283.40
u/l
—
6
10
64
461
1.72
2.50
22.8
8.9
1.16
1.20
mmol/l
4.21
58
427
8
23
3.62
2.31
1.0
1.0
—
—
—
0
0
68
507
1.67
2.29
24.8
9.9
1.16
1.19
mmol/l
2.89
59
450
0
58
0.00
2.09
0.0
1.8
—
232.86
—
0
51
5
11
4.67
1.96
1.4
1.2
6.20
10.09
u/l
—
5
11
8
28
2.97
1.89
1.5
1.5
—
—
—
0
0
7
23
3.15
1.82
1.0
1.3
—
—
—
0
0
7
23
3.15
1.82
1.0
1.3
—
—
—
0
0
7
23
3.15
1.82
1.6
1.3
—
—
—
0
0
42
566
0.63
1.69
3.6
4.8
18.53
21.94
%
1.19
18
279
5
14
3.66
1.63
1.0
1.1
—
—
—
0
0
7
26
2.78
1.60
1.1
1.2
—
—
—
0
0
7
26
2.78
1.60
1.1
1.2
—
—
—
0
0
6
20
3.09
1.60
2.2
3.2
—
—
—
0
0
24
365
0.59
1.58
2.3
2.0
1.52
1.43
mmol/l
0.18
18
304
14
72
2.05
1.55
3.0
1.9
—
—
—
0
0
5
15
3.42
1.53
1.0
1.3
—
—
—
0
0
5
15
3.42
1.53
1.2
1.4
—
247.28
—
0
10
5
15
3.42
1.53
2.2
2.3
—
—
—
0
0
9
38
2.46
1.48
4.1
1.7
—
—
—
0
0
57
706
0.67
1.46
4.6
5.6
2.97
2.81
ug/l
0.05
52
634
5
16
3.20
1.45
4.2
1.3
—
—
—
0
0
43
315
1.53
1.44
5.3
3.0
0.27
0.38
e6/l
0.46
36
237
5
17
3.01
1.37
2.2
2.2
—
—
—
0
0
31
430
0.64
1.36
2.6
3.3
0.66
0.80
ug/l
0.76
21
280
5
18
2.84
1.29
5.4
1.4
—
—
—
0
0
8
35
2.36
1.29
3.4
1.3
—
—
—
0
0
8
37
2.23
1.23
4.5
1.5
—
—
—
0
0
27
189
1.53
1.10
3.6
2.9
0.36
0.46
e6/l
0.19
14
100
5
21
2.43
1.10
4.8
2.0
—
—
—
0
0
7
32
2.25
1.10
3.6
1.3
—
—
—
0
0
50
401
1.39
1.01
5.0
3.2
—
—
—
0
0
12
69
1.81
1.00
8.8
4.1
64.87
49.85
%
1.94
12
64
17
110
1.62
0.96
4.1
3.1
—
—
—
0
0
26
190
1.45
0.87
32.7
9.2
102.77
104.08
mmol/l
0.39
26
190
79
883
0.76
0.84
6.9
7.0
42.04
40.60
mmol/mol
0.58
79
835
26
195
1.41
0.77
3.3
2.8
0.45
0.64
e6/l
0.30
14
104
50
420
1.30
0.72
5.4
3.1
—
—
estimate
—
0
0
5
27
1.88
0.69
1.0
1.1
—
—
—
0
0
80
881
0.78
0.69
5.1
5.3
6.15
6.17
mmol/l
0.06
74
805
29
230
1.33
0.62
4.4
2.9
—
—
—
0
0
45
384
1.25
0.56
3.2
2.5
67.20
71.12
nmol/l
0.57
40
339
15
109
1.42
0.53
1.1
1.4
64.48
16.17
u/ml
—
6
35
9
126
0.69
0.46
1.4
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
193.03
—
0
16
45
408
1.15
0.29
2.6
2.2
79.28
89.99
pmol/l
1.20
33
236
11
86
1.30
0.27
1.9
1.5
—
—
—
0
0
58
540
1.13
0.25
3.4
3.0
—
—
—
0
0
5
40
1.26
0.22
2.4
1.2
—
—
—
0
0
5
41
1.23
0.22
1.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.8
—
3.71
—
0
7
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
21
191
1.12
0.12
3.1
3.0
2.44
2.46
mmol/l
0.15
15
167
38
403
0.92
0.12
5.5
3.7
0.00
0.03
estimate
0.50
14
103
23
215
1.08
0.08
1.8
1.9
314.69
399.81
pmol/l
1.14
18
187
31
295
1.07
0.07
5.6
3.3
0.00
0.00
estimate
-0.00
13
92
51
520
0.97
0.03
5.6
3.7
0.00
0.00
estimate
-0.00
19
115
10
93
1.08
0.02
11.9
9.0
—
—
—
0
0
52
528
0.98
0.01
5.5
3.7
0.00
0.04
estimate
0.50
18
105
29
294
0.98
0.00
5.6
3.9
0.00
0.03
estimate
0.74
16
100
35
345
1.02
0.00
5.0
4.4
5.40
12.71
mg/mmol
1.57
26
249
21
212
0.99
0.00
1.1
1.4
0.75
1.47
u/ml
—
6
53
0
9
0.00
0.00
0.0
1.1
—
7.74
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
12.75
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
7.56
—
0
5
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
10.66
—
0
7
0
5
0.00
-0.00
0.0
3.4
—
40.40
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
8.17
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
1.56
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
51
510
1.00
-0.00
5.6
3.7
0.00
0.00
estimate
-0.00
19
112
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: ERECTILE_EXCLUSION – Erectile dysfunction, exclusion
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).